Show simple item record

dc.contributor.authorBalieva, Flora Nicol
dc.contributor.authorFinlay, Andrew Y.
dc.contributor.authorKupfer, Jörg
dc.contributor.authorAragones, Lucia Tomas
dc.contributor.authorLien, Lars
dc.contributor.authorGieler, Uwe
dc.contributor.authorPoot, Francoise
dc.contributor.authorJemec, Gregor B. E.
dc.contributor.authorMisery, Laurent
dc.contributor.authorKemeny, Lajos
dc.contributor.authorSampogna, Francesca
dc.contributor.authorVan Middendorp, Henriet
dc.contributor.authorHalvorsen, Jon Anders
dc.contributor.authorTernowitz, Thomas
dc.contributor.authorSzepietowski, Jacek C.
dc.contributor.authorPotekaev, Nikolay
dc.contributor.authorMarrón, Servando E.
dc.contributor.authorAltunay, Ilknur K.
dc.contributor.authorSalek, Sam S.
dc.contributor.authorDalgard, Florence
dc.date.accessioned2019-01-21T13:22:31Z
dc.date.available2019-01-21T13:22:31Z
dc.date.created2018-04-04T11:56:46Z
dc.date.issued2018
dc.identifier.citationActa Dermato-Venereologica. 2018, 98 (6), 563-569.
dc.identifier.issn0001-5555
dc.identifier.urihttp://hdl.handle.net/11250/2581574
dc.description.abstractSkin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
dc.description.abstractThe role of therapy in impairing quality of life in dermatological patients: A multinational study
dc.language.isoeng
dc.titleThe role of therapy in impairing quality of life in dermatological patients: A multinational study
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersion
dc.source.pagenumber563-569
dc.source.volume98
dc.source.journalActa Dermato-Venereologica
dc.source.issue6
dc.identifier.doi10.2340/00015555-2918
dc.identifier.cristin1577266
cristin.unitcode209,4,2,0
cristin.unitnameInstitutt for helsefag
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record